In Vitro Diagnostics (IVD)
Post-COVID, is the home testing boom sustainable?
A (Lab Director): Accuracy concerns persist. Home HPV tests have 20% false negative rates. Lab-based PCR with CLIA oversight is still the gold standard. We're seeing patients make treatment decisions based on faulty home results.
B (Diagnostics Entrepreneur): Consumers want convenience. Multiplex molecular tests (COVID + Flu + RSV + Strep at home) will be in every pharmacy by 2027. The technology (LAMP, CRISPR-based) is ready.
C (Regulatory - FDA): The new LDT rule gives us authority to regulate lab-developed tests. Many home-brew IVDs will be pulled from market unless they submit for 510(k) clearance. Expect enforcement in 2026.
D (Public Health): Access inequity persists. Medicaid doesn't reimburse home tests. Low-income patients rely on free clinic swabs. We need universal coverage for OTC IVDs, or we'll widen health disparities.


In some cases, individuals prioritize qualifications that align closely with industry roles. The presence of nvq level 6 construction site management reflects that approach. It offers a structured path based on real job functions. Some also explore The College of Contract Management for comparison. This helps broaden their perspective. It leads to more strategic planning.